Literature DB >> 14526212

Epidemiologic modeling to evaluate prevention of mother-infant HIV transmission in Ontario.

Robert S Remis1, Susan M King, Lee Vernich, Carol Major, Elaine Whittingham.   

Abstract

OBJECTIVES: To evaluate the impact of the Ontario HIV screening program to reduce mother-infant HIV transmission, this study estimated the proportion of preventable transmissions that were prevented.
METHODS: Using an iterative spreadsheet model, incidences of HIV infection, AIDS, and AIDS mortality in Ontario women were estimated by exposure category. The number of HIV-infected infants born to HIV-infected mothers was then estimated from conception and abortion rates of HIV-infected women of childbearing age and surveillance data. Finally, the proportion of HIV-infected mothers who received antiretroviral prophylaxis (ARP) was assessed.
RESULTS: HIV prevalence in 2001 among women of childbearing age was 1.05 per 1000. From 1984-2001, 764 infants were born to HIV-infected mothers and 180 were infected. From mid-1994-2001, 214 (39%) of the estimated 544 HIV-infected mothers were diagnosed; almost all received ARP. Of 118 preventable infections among infants born in this period, 39 (33%) were prevented. In 2001, only 46% of preventable infections were prevented and 11 preventable transmissions occurred.
CONCLUSIONS: HIV prevalence among women in Ontario increased >4-fold from 1990 to 2001. Fewer than half of HIV-infected mothers received ARP and preventable HIV infections continue to occur. Measures to further increase uptake of prenatal HIV screening must be instituted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526212     DOI: 10.1097/00126334-200310010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  1 in total

1.  Screening HIV in pregnancy: a survey of prenatal care patients.

Authors:  Veronique Dorval; Kerri Ritchie; Andrée Gruslin
Journal:  Can J Public Health       Date:  2007 Sep-Oct
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.